Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study

BACKGROUND: The benefits and tolerability of transarterial chemoembolization (TACE) combined with regorafenib as a second-line therapy has not been reported for unresectable hepatocellular carcinoma (HCC). This study aimed to explore the benefits and tolerability of TACE combined with second-line re...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Yue, Cao, Guang, Sun, Bin, Wang, Jian, Yan, Dong, Xu, Haifeng, Shi, Qinsheng, Liu, Zechuan, Zhi, Weihua, Xu, Liang, Liu, Bojun, Zou, Yinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529854/
https://www.ncbi.nlm.nih.gov/pubmed/34670512
http://dx.doi.org/10.1186/s12876-021-01967-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8529854/
https://www.ncbi.nlm.nih.gov/pubmed/34670512
http://dx.doi.org/10.1186/s12876-021-01967-3

Ejemplares similares